The burden on Europapi continues to grow.
The specialist in active ingredients, formerly in the fold of Sanofi, has just suspended
“
until further notice
”
the production of one of its six industrial sites, that of Brindisi in Italy.
This factory has so far produced eleven active ingredients, which are essentially anti-infectives that have fallen into the public domain.
Thus spiramycin, intended to treat dental abscesses, or rifampicin, an anti-tuberculosis drug.
In mid-February, a routine stability investigation of chemicals manufactured at this plant found deficiencies, which led to an additional investigation and then an audit.
Carried out from March 4 to 8, this audit identified a quality control defect,
“
attributable to potential shortcomings at the local level
”
, only in Brindisi.
They are today the subject of a
“
thorough investigation
”
, specifies Euroapi.
A site about to be sold
In the meantime, the 2024 financial outlook is also suspended…
This article is reserved for subscribers.
You have 69% left to discover.
Flash sale
€4.49/month for 12 months
I ENJOY IT
Already subscribed?
Log in